
|Articles|September 1, 2002
Up to 40% of cancers may not present clinically
Author(s)Scott Tennant
Seattle-Despite the way it was portrayed in some of the lay media, the authors of a recent study on the "overdiagnosis" of prostate cancer insist their work should not be construed as hostile to the practice of PSA screening. In fact, says one investigator, results of the study paint an overall favorable picture of screening.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer
5











